Another cancer patient has filed a Taxotere lawsuit against manufacturer Sanofi after being left with permanent alopecia after chemo.

The Arizona plaintiff, Susan H., was diagnosed with breast cancer in April 2011. Shortly after her diagnosis, she began a treatment regimen for several months with some form of Taxotere — between July 12, 2011 and Oct. 25 later that year. However, Susan suffered permanent alopecia after chemo treatment was over.

The lawsuit was filed on multiple counts, including failure to warn, negligence, fraudulent misrepresentation and concealment, and several others.

What is Alopecia?

Hair loss, also known as alopecia, is the most commonly known symptom associated with chemotherapy treatment for cancer patients. Most patients go into chemotherapy aware that they run a risk of losing their hair to alopecia from the treatment. However, patients generally expect that, after chemo is over, their hair will grow back.

Unfortunately, a growing number of cancer patients are discovering that they are left with permanent alopecia after chemo using Taxotere, unable to grow their hair back at all.

Background of Taxotere

Taxotere (generic name docetaxel) is a commonly used chemotherapy drug manufactured by pharmaceutical giant Sanofi. Taxotere was first approved by the U.S. Food and Drug Administration (FDA) back in 1996, and has grown steadily more popular over the years.

In order to fight cancer, Taxotere prevents cancer cells from growing, which prevents the cancer from spreading. However, it may be that the function of Taxotere working to prevent the growth of cancer cells can also cause permanent alopecia.

Unfortunately, many patients treated with docetaxel drugs are being left with problems growing back their hair, or even permanent alopecia after chemo.

Filing a Taxotere Lawsuit Over Permanent Alopecia After Chemo

According to this permanent hair loss lawsuit and others like it, Sanofi either knew or should have known that their drug Taxotere was linked with permanent hair loss complications.

Plaintiffs allege that the company not only failed to adequately warn about this risk, but even actively concealed information, instead promoting the drug as both safe and effective. Lawsuits claim that Sanofi has been aware of reports and studies linking Taxotere to permanent hair loss after chemotherapy since as far back as its approval in 1996.

If you or someone you love has suffered from permanent alopecia after chemo treatment with Taxotere or another docetaxel medication, you may be able to gain some kind of financial compensation by joining Taxotere permanent hair loss litigation.

Filing a Taxotere lawsuit cannot take away the pain and suffering a cancer patient endures, or take away the effects of permanent alopecia after chemo, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Alopecia Lawsuit is Case No. 2:17-cv-05647-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.